These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 15928641)
1. A pilot study on the use of topical tazarotene to treat squamous cell carcinoma in situ. Bardazzi F; Bianchi F; Parente G; Guareschi E; Landi C J Am Acad Dermatol; 2005 Jun; 52(6):1102-4. PubMed ID: 15928641 [No Abstract] [Full Text] [Related]
2. Proceedings: Use of 5 fluorouracil in the topical therapy of skin cancer: a review of 157 patients. Litwin MS; Ryan RF; Ichinose H; Reed RR; Kremetz ET Proc Natl Cancer Conf; 1972; 7():549-61. PubMed ID: 4764922 [No Abstract] [Full Text] [Related]
3. Topical chemotherapy of basal and squamous skin cancers with 5-fluorouracil cream. Litwin MS; Krementz ET Panminerva Med; 1974 Mar; 16(3):84-5. PubMed ID: 4449647 [No Abstract] [Full Text] [Related]
4. The sap from Euphorbia peplus is effective against human nonmelanoma skin cancers. Ramsay JR; Suhrbier A; Aylward JH; Ogbourne S; Cozzi SJ; Poulsen MG; Baumann KC; Welburn P; Redlich GL; Parsons PG Br J Dermatol; 2011 Mar; 164(3):633-6. PubMed ID: 21375515 [TBL] [Abstract][Full Text] [Related]
5. Evidence of increased apoptosis and reduced proliferation in basal cell carcinomas treated with tazarotene. Orlandi A; Bianchi L; Costanzo A; Campione E; Giusto Spagnoli L; Chimenti S J Invest Dermatol; 2004 Apr; 122(4):1037-41. PubMed ID: 15102095 [TBL] [Abstract][Full Text] [Related]
6. Preliminary observations on the use of topical tazarotene to treat basal-cell carcinoma. Peris K; Fargnoli MC; Chimenti S N Engl J Med; 1999 Dec; 341(23):1767-8. PubMed ID: 10610445 [No Abstract] [Full Text] [Related]
7. Treatment of lentigo maligna with tazarotene 0.1% gel. Chimenti S; Carrozzo AM; Citarella L; De Felice C; Peris K J Am Acad Dermatol; 2004 Jan; 50(1):101-3. PubMed ID: 14699375 [TBL] [Abstract][Full Text] [Related]
8. Tazarotene 0.1% cream for the treatment of photodamage. Phillips TJ Skin Therapy Lett; 2004 Apr; 9(4):1-2. PubMed ID: 15146262 [TBL] [Abstract][Full Text] [Related]
9. Confluent and reticulated papillomatosis: response to tazarotene. Bowman PH; Davis LS J Am Acad Dermatol; 2003 May; 48(5 Suppl):S80-1. PubMed ID: 12734485 [TBL] [Abstract][Full Text] [Related]
10. Tazarotene-induced gene 3 is suppressed in basal cell carcinomas and reversed in vivo by tazarotene application. Duvic M; Ni X; Talpur R; Herne K; Schulz C; Sui D; Ward S; Joseph A; Hazarika P J Invest Dermatol; 2003 Oct; 121(4):902-9. PubMed ID: 14632211 [TBL] [Abstract][Full Text] [Related]
11. Treatment of ichthyosiform diseases with topically applied tazarotene: risk of systemic absorption. Nguyen V; Cunningham BB; Eichenfield LF; Alió AB; Buka RL J Am Acad Dermatol; 2007 Nov; 57(5 Suppl):S123-5. PubMed ID: 17938025 [No Abstract] [Full Text] [Related]
13. A pilot study of iontophoretic cisplatin chemotherapy of basal and squamous cell carcinomas of the skin. Chang BK; Guthrie TH; Hayakawa K; Gangarosa LP Arch Dermatol; 1993 Apr; 129(4):425-7. PubMed ID: 8466212 [No Abstract] [Full Text] [Related]
14. Dermoscopic monitoring of tazarotene treatment of superficial basal cell carcinoma. Peris K; Ferrari A; Fargnoli MC; Piccolo D; Chimenti S Dermatol Surg; 2005 Feb; 31(2):217-20. PubMed ID: 15762218 [No Abstract] [Full Text] [Related]
15. Treatment of psoriatic nails with tazarotene cream 0.1% vs. clobetasol propionate 0.05% cream: a double-blind study. Rigopoulos D; Gregoriou S; Katsambas A Acta Derm Venereol; 2007; 87(2):167-8. PubMed ID: 17340027 [No Abstract] [Full Text] [Related]
16. Response of carcinoma in situ (actinic keratosis) to green tea concentrate plus capsicum. Morré DJ; Geilen CC; Welch AM; Morré DM J Diet Suppl; 2009; 6(4):385-9. PubMed ID: 22435520 [TBL] [Abstract][Full Text] [Related]
17. Successful treatment of Favre-Racouchot disease with 0.05% tazarotene gel. Rallis E; Karanikola E; Verros C Arch Dermatol; 2007 Jun; 143(6):810-2. PubMed ID: 17576962 [No Abstract] [Full Text] [Related]